ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions
View by Date

Monday, November 6, 2017

2:30PM-4:00PM
Abstract Number: 1800
Do Patient Reported Outcome Measurement Information System (PROMIS) Computer Adaptive Tests Correlate with Disease Activity in Juvenile Idiopathic Arthritis?
Measures and Measurement of Healthcare Quality
2:30PM-4:00PM
Abstract Number: 1821
Dose Reduction of Baricitinib in Patients with Rheumatoid Arthritis Achieving Sustained Disease Control: Results of a Prospective Study
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy I: Outcomes Therapy
2:30PM-4:00PM
Abstract Number: 1798
Effective Implementation and Evaluation of Quality Improvement Initiatives in a Safety Net Hospital Rheumatology Clinic
Measures and Measurement of Healthcare Quality
2:30PM-4:00PM
Abstract Number: 1850
Efficacy of Zoledronic Acid and Denosumab in the Treatment of Patients with Low Back Pain and Modic Changes: A Proof of Principle Trial
ACR/ARHP Combined: Orthopedics and Rehabilitation Science
2:30PM-4:00PM
Abstract Number: 1838
Estimating Duration of Response in Systemic Lupus Erythematosus (SLE) Trials
Systemic Lupus Erythematosus – Clinical Aspects and Treatment II: Clinical Trial Design and Outcome Measures
2:30PM-4:00PM
Abstract Number: 1824
Evaluation of Pneumococcal and Tetanus Vaccine Responses in Patients with Rheumatoid Arthritis Receiving Baricitinib: Results from a Long-Term Extension Trial Substudy
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy I: Outcomes Therapy
2:30PM-4:00PM
Abstract Number: 1853
Exercise and Adherence over Two Years: Beliefs of Adults with Knee Osteoarthritis
ACR/ARHP Combined: Orthopedics and Rehabilitation Science
2:30PM-4:00PM
Abstract Number: 1855
Feasibility and Preliminary Effects of a Novel Rehabilitation Strategy to Improve Hand and Arm Function in Systemic Sclerosis
ACR/ARHP Combined: Orthopedics and Rehabilitation Science
2:30PM-4:00PM
Abstract Number: 1832
Gut Dysbiosis Contributes to Autoimmune Pathogenesis in Lupus-Prone Mice
Systemic Lupus Erythematosus – Animal Models
2:30PM-4:00PM
Abstract Number: 1854
Identifying Vulnerable Patient Populations Based on Age and Physical Function on Clinical Outcomes Following Total Knee Arthroplasty
ACR/ARHP Combined: Orthopedics and Rehabilitation Science
2:30PM-4:00PM
Abstract Number: 1795
IL-7 in Primary Sjogren Syndrome (pSS) Is Secreted By Salivary Gland Epithelial Cells after IFN Stimulation and Is Associated with B-Cell Activation
Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis: Unexpected Effects from "Well-Known" Molecules
2:30PM-4:00PM
Abstract Number: 1851
Improving Walking Ability in Degenerative Lumbar Spinal Stenosis: A Randomized Trial Comparing 2 Self-Management Training Programs
ACR/ARHP Combined: Orthopedics and Rehabilitation Science
2:30PM-4:00PM
Abstract Number: 1846
Increased CD38hiCD27+ Plasmablast Frequency in Remission Predicts Relapsing Disease in Granulomatosis with Polyangiitis Patients
Vasculitis II: Biomarkers and Disease Activity
2:30PM-4:00PM
Abstract Number: 1797
Insights from Treating to Target in Rheumatoid Arthritis at an Academic Medical Center
Measures and Measurement of Healthcare Quality
2:30PM-4:00PM
Abstract Number: 1793
Interleukin-17 Is Not a Determinant for the Pro- or Anti-Inflammatory Character of Interleukin-22 in Experimental Arthritis
Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis: Unexpected Effects from "Well-Known" Molecules
  • «Previous Page
  • 1
  • …
  • 56
  • 57
  • 58
  • 59
  • 60
  • …
  • 65
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology